YPB Confirm US Patent Allowance, Strengthening MotifMicro’s Position
There has been a promising development for authentication and consumer engagement solutions provider YPB Group Limited (ASX:YPB) with the US patent regulatory body opening the way for the group to generate further income from its MotifMicro authentication technology.
In formal terms, the US Patent and Trademark Office has issued a Notice of Allowance for MIT Case No: 15231L “Rare Earth Spatial/Spectral Microparticle Barcodes for Labelling of Objects and Tissues, under US Application No.: 15/387,889”.
With MotifMicro having an existing family of patents granted in the US, there are significant benefits from having key additional claims allowed by the US Patent and Trademark Office as this extends the coverage of the patent family.
The novelty and power of MotifMicro is illustrated by the allowance’s coverage of, amongst other aspects, biological materials such as nucleic acids.
The extension is highly commercially significant as it confirms MotifMicro’s serialisation capability, one of its primary commercial benefits along with smartphone readability.
Consumers and governments to push for serialisation
Serialisation, or unique digital identities for every item produced, will eventually become widespread due to government fiat in certain sectors and/or consumer demand for authenticity and provenance.
The extension of the patent coverage also supports the exploration of alternative funding plans for the development of MotifMicro.
Many industries are interested in preventing spoofing or counterfeiting of a wide range of materials.
For example, one of YPB’s China clients currently marks glue used in global brand consumer goods with YPB technology to prevent substitution.
Discussing the significance of this development from an operational perspective while also reflecting on the potential opportunities for exploring alternative development funding plans, chief executive John Houston said, “This Formal allowance by the US Patent and Trademark Office is a vital step towards confirming MotifMicro’s power to securely mark products and packaging globally, cementing its commercial value and possibly opening value-creating funding sources for its second generation development.”
This news comes on the back of other important developments in November, including the negotiation of a new contract and FDA certification for MotifMicro.
These events have been the catalyst for a 40% increase in the company’s share price during the month, and this momentum could be sustained on the back of today’s news.
YPB provides the full package
MotifMicro is an extension of an end to end solution whereby YPB’s smartphone authentication solutions and its SaaS Connect platform, creates ‘smart’ product packaging, opening cost-effective, digital and direct marketing channels between brands and their consumers.
Connect gathers actionable data on consumer preferences, allowing the hosting of tailored marketing campaigns directly back to the scanning smartphone.
YPB’s technology is trusted by the world’s largest passport issuing nation to ensure the authenticity of its passports.
Management is currently focused on the rapidly growing Australian, South East Asian, and Chinese markets.
Particular areas of focus are dairy, cannabis, alcohol and cosmetics where the viral growth of fake products, especially in Asia, affects brand value and endangers consumers.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.